Skip to main content
SpringerLink
Log in

Diquafosol

DE 089, Diquafosol Tetrasodium, INS 365, INS 365 Ophthalmic, INS 365 Respiratory, KPY 998

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Inspire Pharmaceuticals. Inspire Pharmaceuticals Announces FDA Acceptance Of Diquafosol NDA for Filing. Media Release: 9 Sep 2003. Available from URL: http://www.inspirepharm.com

    Google Scholar 

  2. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals’ Diquafosol NDA Granted Priority Review by the FDA. Media Release: 31 Jul 2003. Available from URL: http://www.nrpeuro.com

    Google Scholar 

  3. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals, Inc. reports positive results for novel therapeutic for dry eye disease. Media Release: [2 pages], 11 May 1999

    Google Scholar 

  4. Evans R, Johnson F, Kellerman D, et al. Aerosolized INS365 for COPD: enhanced deposition and clearance using the AERx delivery system. American Journal of Respiratory and Critical Care Medicine 161 (Suppl.): 815, Part 2, Mar 2000

    Google Scholar 

  5. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals reports positive phase I results for INS365; announces new clinical collaboration with cystic fibrosis foundation. Media Release: [2 pages], 17 Oct 1998

    Google Scholar 

  6. Kellerman DJ, Bennett WD, Zeman KL, et al. Dose response relationship of the P2Y2 agonist INS365 on mucociliary clearance in smokers. Journal of Allergy and Clinical Immunology 107 (Abstr. Suppl.): 164–165, Feb 2001

    Google Scholar 

  7. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals, Inc. presents positive phase II data for INS365 ophthalmic for dry eye, and launches first phase I/II clinical trial for INS37217 ophthalmic for retinal detachment. Media Release: [3 pages], 3 May 2001. Available from URL: http://www.inspirepharm.com

    Google Scholar 

  8. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals Announces Results of Second Phase III Trial of INS365 Ophthalmic for The Treatment of Dry Eye. Media Release: 18 Jun 2002. Available from URL: http://www.inspirepharm.com

    Google Scholar 

  9. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals Announces Timing of Dry Eye NDA Based on Pre-NDA Meeting with the FDA — Also Provides Guidance on 2003 Revenues. Media Release: 7 Jan 2003. Available from URL: http://www.inspirepharm.com

    Google Scholar 

  10. Inspire Pharmaceuticals Inc. Inspire Pharmaceuticals Announces Results of Phase IIIb Study in Dry Eye. Media Release: 13 Aug 2003. Available from URL: http://www.inspirepharm.com

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Diquafosol. Drugs R&D 4, 359–362 (2003). https://doi.org/10.2165/00126839-200304060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304060-00005

Keywords

Search

Navigation